A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease

Colloids and Surfaces B: Biointerfaces

Volumn 143, Issue , 2016, Pages 327-335

  Beloqui, Ana ^a   Memvanga, Patrick B ^a,b   Coco, Régis ^a   Reimondez Troitiño, Sonia ^c,d   Alhouayek, Mireille ^a   Muccioli, Giulio G ^a   Alonso, María José ^c   Csaba, Noemi ^c   de la Fuente, María ^d   Préat, Véronique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF KINSHASA   (Congo)

^c University of Santiago de Compostela ^*  (Spain)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

Curcumin; IBD; Lipids; Nanocapsules; NLC; SNEDDS

Indexed keywords

ENZYME INHIBITION; LIPIDS; NANOCAPSULES; PHYSIOLOGY;

ACTIVATED MACROPHAGES; ANTI-INFLAMMATORY DRUGS; CURCUMIN; INFLAMMATORY BOWEL DISEASE; NANOSTRUCTURED LIPID CARRIER (NLC); NEUTROPHIL INFILTRATION; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM (SNEDDS); SNEDDS;

DISEASES;

CURCUMIN; DEXTRAN SULFATE; LIPID CORE SHELL PROTAMINE NANOCAPSULE; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DRUG CARRIER; LIPID; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACO 2 CELL LINE; CANCER CELL LINE; CELL MEMBRANE PERMEABILITY; CHEMICAL COMPOSITION; COLITIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IC50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; J774 CELL LINE; MACROPHAGE ACTIVATION; MICROSCOPY; MOUSE; NANOENCAPSULATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; SUSPENSION; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CACO-2 CELL LINE; CELL LINE; CELL SURVIVAL; CHEMICALLY INDUCED; CHEMISTRY; CONFOCAL MICROSCOPY; CYTOLOGY; DRUG EFFECTS; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASES; MACROPHAGE; METABOLISM; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CACO-2 CELLS; CELL LINE; CELL SURVIVAL; COLITIS; CURCUMIN; DEXTRAN SULFATE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LIPIDS; MACROPHAGES; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NANOPARTICLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84962249816     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.03.038     Document Type: Article

References (47)

1. Lamprecht A., Schäfer U., Lehr C.M. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 2001, 18:788-793.
2. Abraham C., Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361:2066-2078.
3. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 2010, 28:573-621.
4. Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 2010, 24:157-165.
5. Yang Y.X., Lichtenstein G.R. Corticosteroids in Crohn's disease. Am. J. Gastroenterol. 2002, 97:803-823.
6. Stallmach A., Hagel S., Bruns T. Adverse effects of biologics used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 2010, 24:167-182.
7. Grimpen F., Pavli P. Advances in the management of inflammatory bowel disease. Intern. Med. J. 2010, 40:258-264.
8. Collnot E.M., Ali H., Lehr C.M. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J. Control. Release 2012, 161:235-246.
9. Ulbrich W., Lamprecht A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J. R. Soc. Interface 2010, 7(Suppl. 1):S55-66.
10. Lim S.B., Banerjee A., Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release 2012, 163:34-45.
11. Schneider H., Braun A., Füllekrug J., Stremmel W., Ehehalt R. Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation. Int. J. Mol. Sci. 2010, 11:4149-4164.
12. Landesman-Milo D., Peer D. Altering the immune response with lipid-based nanoparticles. J. Control. Release 2012, 161:600-608.
13. Sugimoto K., Hanai H., Tozawa K., Aoshi T., Uchijima M., Nagata T., Koide Y. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002, 123:1912-1922.
14. Beloqui A., Coco R., Memvanga P.B., Ucakar B., des Rieux A., Préat V. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int. J. Pharm. 2014, 473:203-212.
15. Bernkop-Schnürch A. Nanocarrier systems for oral drug delivery: do we really need them?. Eur. J. Pharm. Sci. 2013, 49:272-277.
16. Beloqui A., Coco R., Alhouayek M., Solinís M.A., Rodríguez-Gascón A., Muccioli G.G., Préat V. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int. J. Pharm. 2013, 454:775-783.
17. Beloqui A., Solinís M.A., Rodríguez-Gascón A., Almeida A.J., Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine 2016, 12:143-161.
18. Beloqui A., Solinís M., Rieux A., Préat V., Rodríguez-Gascón A. Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int. J. Pharm. 2014, 468:105-111.
19. Rescigno M., Urbano M., Valzasina B., Francolini M., Rotta G., Bonasio R., Granucci F., Kraehenbuhl J.P., Ricciardi-Castagnoli P. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2001, 2:361-367.
20. Memvanga P.B., Coco R., Préat V. An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with b-arteether. J. Control. Release 2013, 172:904-913.
21. Beloqui A., Solinís M.A., Delgado A., Evora C., del Pozo-Rodríguez A., Rodríguez-Gascón A. Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological factors. Eur. J. Pharm. Biopharm. 2013, 84:309-314.
22. Beloqui A., Solinís M.A., Delgado A., Evora C., Isla A., Rodríguez-Gascón A. Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. J. Microencapsul. 2014, 31:1-8.
23. Calvo P., Remunan-López C., Vila-Jato J.L., Alonso M.J. Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polym. Sci. 1997, 275:46-53.
24. Memvanga P.B., Préat V. Formulation design and in vivo antimalarial evaluation of lipid-based drug delivery systems for oral delivery of beta-arteether. Eur. J. Pharm. Biopharm. 2012, 82:112-119.
25. Beloqui A., Solinís M.A., Rodríguez-Gascón A., del Pozo- Rodríguez A., des Rieux A., Préat V. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J. Control. Release 2013, 166:115-123.
26. Chereddy K.K., Coco R., Memvanga P.B., Ucakar B., des Rieux A., Vandermeulen G., Préat V. Combined effect of PLGA and curcumin on wound healing activity. J. Control. Release 2013, 171:208-215.
27. Memvanga P.B., Mbinze J.K., Rozet E., Hubert P., Préat V., Marini R.D. Development of a liquid chromatographic method for the simultaneous quantification of curcumin β-arteether, tetrahydrocurcumin and dihydroartemisinin. Application to lipid-based formulations. J. Pharm. Biomed. Anal. 2014, 88:447-456.
28. Cui J., Yu B., Zhao Y., Zhu W., Li H., Lou H., Zhai G. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int. J. Pharm. 2009, 371:148-155.
29. des Rieux A., Ragnarsson E.G., Gullberg E., Préat V., Schneider Y.J., Artursson P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 2005, 25:455-465.
30. Coco R., Plapied L., Pourcelle V., Jerome C., Brayden D.J., Schneider Y.J., Préat V. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int. J. Pharm. 2013, 440:3-12.
31. Kunwar A., Barik A., Pandey R., Priyadarsini K.I. Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim. Biophys. Acta 2006, 1760:1513-1520.
32. Fernandes C.A., Fievez L., Neyrinck A.M., Delzenne N.M., Bureau F., Vanbever R. Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages. Biochem. Biophys. Res. Commun. 2012, 420:857-861.
33. Kitamura H., Ito M., Yuasa T., Kikuguchi C., Hijikata A., Takayama M., Kimura Y., Yokoyama R., Kaji T., Ohara O. Genome-wide identification and characterization of transcripts translationally regulated by bacterial lipopolysaccharide in macrophage-like J774.1 cells. Physiol. Genomics 2008, 33:121-132.
34. Laroui H., Dalmasso G., Nguyen H.T., Yan Y., Sitaraman S.V., Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010, 138:843-853. e841-e842.
35. Melgar S., Karlsson A., Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G1328-1338.
36. Alhouayek M., Lambert D.M., Delzenne N.M., Cani P.D., Muccioli G.G. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J. 2011, 25:2711-2721.
37. Alhouayek M., Bottemanne P., Subramanian K.V., Lambert D.M., Makriyannis A., Cani P.D., Muccioli G.G. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis. FASEB J. 2015, 29:650-661.
38. Leung M.H., Kee T.W. Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen. Langmuir 2009, 25:5773-5777.
39. Krishna G., Chen K., Lin C., Nomeir A.A. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int. J. Pharm. 2001, 222:77-89.
40. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv. Drug Deliv. Rev. 2007, 59:1073-1083.
41. Laroui H., Wilson D.S., Dalmasso G., Salaita K., Murthy N., Sitaraman S.V., Merlin D. Nanomedicine in GI. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300:G371-383.
42. Schmidt C., Lautenschlaeger C., Collnot E.-M., Schumann M., Bojarski C., Schulzke J.-D., Lehr C.-M., Stallmach A. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa-a first in vivo study in human patients. J. Control. Release 2013, 165:139-145.
43. Laroui H., Sitaraman S.V., Merlin D. Gastrointestinal delivery of anti-inflammatory nanoparticles. Methods Enzymol. 2012, 509:101-125.
44. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2009, 41:40-59.
45. Hiratsuka T., Inomata M., Hagiwara S., Kono Y., Shiraishi N., Noguchi T., Kitano S. Bolus injection of newly synthesized vitamin E derivative ETS-GS for the treatment of acute severe ulcerative colitis in a mouse model. New vitamin E derivative for acute severe UC. Int. J. Colorectal Dis. 2013, 28:305-311.
46. Harel-Adar T., Ben Mordechai T., Amsalem Y., Feinberg M.S., Leor J., Cohen S. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1827-1832.
47. Ikehara Y., Shiuchi N., Kabata-Ikehara S., Nakanishi H., Yokoyama N., Takagi H., Nagata T., Koide Y., Kuzushima K., Takahashi T., Tsujimura K., Kojima N. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett. 2008, 260:137-145.